1. Pink Sheet
  2. >>Geography

Accelerated Assessment Decision ‘Imminent’ For Two Products In EMA’s PRIME Scheme

 
• By Neena Brizmohun

The sponsors of two products in the European Medicines Agency’s popular PRIME scheme for speeding patient access to drugs for unmet medical needs appear to be close to filing their applications for marketing authorization. Five more products were accepted on the scheme this week.

airport runway under the sun as background
The EMA's PRIME scheme should speed time to market • Source: Shuttestock

Two of the investigational products in the European Medicines Agency’s priority medicines (PRIME) scheme for drugs for unmet medical need have now reached the stage where decisions are imminent on whether they will be accepted for review under the EU’s accelerated assessment procedure.

Jordi Llinares Garcia of the EMA revealed this development on May 19 at a meeting the agency hosted at its headquarters in London to mark the first anniversary of PRIME...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

 
• By Vibha Sharma

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.

Why Hympavzi Secured English Funding For Hemophilia B But Not Hemophilia A

 
• By Neena Brizmohun

Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.

Europe’s UPC Issues Landmark Ruling On Second Medical Use Claims

 
• By Neena Brizmohun

The verdict by the Unified Patent Court in the dispute between Sanofi/Regeneron Pharmaceuticals and Amgen explains what companies should look out for when deciding whether infringement has taken place when it comes to second medical use patents.